Modi-Mundipharma Pvt. Ltd. & Anr. v. Win Health Pharma Through: Its Proprietor Mr. Sanjay Seth & Anr.

In the pharmaceutical world, a brand name is not just a label on a box; it is a promise of trust built over decades. When a competitor attempts to ride on that trust by mimicking not only the name but also the look and feel of an established product, the stakes are nothing short of patient safety and corporate survival. This is the story of how one of India's leading pharmaceutical companies drew a hard line against a copycat, and why the court stood firmly by its side.

Modi-Mundipharma Pvt. Ltd., a well-established pharmaceutical company, had built a powerful family of trademarks under the 'CONTIN' series. Over the years, the company had cultivated enormous goodwill in the market, backed by staggering sales figures exceeding Rs. 2,000 crores. The 'CONTIN' brand had become synonymous with quality and reliability in its therapeutic segment. Into this carefully built ecosystem stepped Win Health Pharma, which began using the mark 'CARDIOCONTIN' for a product in the same category. Modi-Mundipharma viewed this not as coincidence, but as a deliberate attempt to trade off its hard-earned reputation. The similarity was not limited to the name alone; the packaging and overall trade dress were reportedly near-identical, raising serious concerns about consumer deception.

Modi-Mundipharma moved the Delhi High Court seeking an ex parte ad interim injunction, arguing that the use of 'CARDIOCONTIN' amounted to a prima facie infringement of its established 'CONTIN' series trademarks. The company highlighted its prior use, the immense goodwill associated with the brand, and the overwhelming likelihood of confusion among consumers, doctors, and chemists, given that both products were of the same type and shared strikingly similar packaging. The Defendant, Win Health Pharma, had only recently adopted the mark, which further weakened its position at this preliminary stage. The court, however, reserved the question regarding the use of the standalone mark 'WIN' for a later hearing, after formal notice was served to the Defendants, ensuring that the broader trademark dispute would be examined in full.

The Delhi High Court ruled in favor of Modi-Mundipharma, granting the ex parte ad interim injunction against the use of the mark 'CARDIOCONTIN'. The court found that the Plaintiff had successfully established a prima facie case of trademark infringement. The reasoning rested on three critical pillars: the Plaintiff's clear prior use of the 'CONTIN' series, the extensive goodwill reflected in sales figures exceeding Rs. 2,000 crores, and the high likelihood of confusion created by the identical product category combined with near-identical packaging. The court was convinced that allowing the Defendant to continue using the impugned mark during the pendency of the suit would cause irreparable harm to the Plaintiff's brand equity and consumer trust. The matter concerning the 'WIN' mark was kept open for adjudication after notice.

For founders and brand builders, this case delivers a powerful lesson: trademark protection is not just about registering a name, it is about building an evidentiary fortress around it. If you want to win an infringement battle at the earliest stage, you need documented proof of prior use, robust sales and advertising data that quantifies your goodwill, and clear evidence of consumer confusion, whether through similar marks, identical product categories, or copied trade dress. A recently filed or adopted mark by a competitor offers little defense when weighed against decades of established reputation. Invest in your brand's distinctiveness, protect its visual identity as fiercely as its name, and keep your records airtight, because when a copycat comes knocking, your paperwork will be your strongest weapon.